Payment overview · 2025
General Payments
$271.69
14 reported records · 9 companies
Healthcare provider profile · identity verified
Galina Vayner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORCROSS, GA · NPI 1891786497
Verified facts
What the public records show
CMS Open Payments records show Galina Vayner, MD received $271.69 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic, Rybelsus, Trelegy Ellipta, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 489 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.90 | 20.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.30 | 18.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.16 | 16.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.27 | 13.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.52 | 7.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.40 | 7.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.33 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.67 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.69 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 489 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 91 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 341 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 203 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 234 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
74 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
489 | 130 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
234 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
341 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
203 | 57 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
91 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1646 | 436 |
| Metformin Hcl | Metformin Hcl | 1479 | 371 |
| Omeprazole | Omeprazole | 1469 | 356 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1415 | 409 |
| Alendronate Sodium | Alendronate Sodium | 981 | 282 |
| Gabapentin | Gabapentin | 852 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 805 | 195 |
| Lisinopril | Lisinopril | 749 | 207 |
| Tamsulosin Hcl | Tamsulosin Hcl | 684 | 179 |
| Losartan Potassium | Losartan Potassium | 653 | 173 |
| Diclofenac Sodium | Diclofenac Sodium | 635 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 597 | 185 |
| Pravastatin Sodium | Pravastatin Sodium | 589 | 156 |
| Metoprolol Succinate | Metoprolol Succinate | 566 | 145 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 557 | 167 |
| Furosemide | Furosemide | 526 | 137 |
| Linzess | Linaclotide | 525 | 153 |
| Farxiga | Dapagliflozin Propanediol | 489 | 130 |
| Glipizide | Glipizide | 469 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 458 | 138 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 446 | 110 |
| Simvastatin | Simvastatin | 420 | 108 |
| Clonidine Hcl | Clonidine Hcl | 411 | 157 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 403 | 116 |
| Hydralazine Hcl | Hydralazine Hcl | 395 | 93 |
| Meclizine Hcl | Meclizine Hcl | 382 | 119 |
| Carvedilol | Carvedilol | 375 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 374 | 92 |
| Fluticasone Propionate | Fluticasone Propionate | 355 | 113 |
| Ozempic | Semaglutide | 341 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 339 | 168 |
| Famotidine | Famotidine | 337 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 329 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 328 | 87 |
| Atenolol | Atenolol | 318 | 83 |
| Montelukast Sodium | Montelukast Sodium | 308 | 80 |
| Trazodone Hcl | Trazodone Hcl | 307 | 91 |
| Eliquis | Apixaban | 300 | 69 |
| Allopurinol | Allopurinol | 296 | 80 |
| Spironolactone | Spironolactone | 293 | 88 |
| Glipizide Er | Glipizide | 288 | 70 |
| Donepezil Hcl | Donepezil Hcl | 287 | 54 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 281 | 144 |
| Potassium Chloride | Potassium Chloride | 266 | 67 |
| Ibuprofen | Ibuprofen | 263 | 126 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 261 | 82 |
| Meloxicam | Meloxicam | 259 | 116 |
| Tramadol Hcl | Tramadol Hcl | 243 | 91 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 242 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 234 | 63 |
| Finasteride | Finasteride | 231 | 54 |
| Alprazolam | Alprazolam | 208 | 78 |
| Tresiba Flextouch U-100 | Insulin Degludec | 208 | 43 |
| Rybelsus | Semaglutide | 203 | 57 |
| Xarelto | Rivaroxaban | 203 | 42 |
| Sertraline Hcl | Sertraline Hcl | 196 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 193 | 60 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 189 | 54 |
| Azelastine Hcl | Azelastine Hcl | 187 | 47 |
| Azithromycin | Azithromycin | 176 | 153 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 166 | 44 |
| Januvia | Sitagliptin Phosphate | 164 | 43 |
| Ketoconazole | Ketoconazole | 164 | 57 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 152 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 148 | 44 |
| Fenofibrate | Fenofibrate Nanocrystallized | 144 | 39 |
| Myrbetriq | Mirabegron | 144 | 40 |
| Creon | Lipase/Protease/Amylase | 140 | 44 |
| Lidocaine | Lidocaine | 140 | 49 |
| Nitroglycerin | Nitroglycerin | 140 | 55 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 138 | 33 |
| Prednisone | Prednisone | 136 | 107 |
| Vascepa | Icosapent Ethyl | 135 | 30 |
| Glimepiride | Glimepiride | 128 | 25 |
| Jardiance | Empagliflozin | 127 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 122 | 31 |
| Megestrol Acetate | Megestrol Acetate | 122 | 30 |
| Valsartan | Valsartan | 121 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 109 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 24 |
| Clonazepam | Clonazepam | 105 | 28 |
| Lovastatin | Lovastatin | 105 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 32 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 104 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 102 | 79 |
| Procto-Med Hc | Hydrocortisone | 99 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 31 |
| Lorazepam | Lorazepam | 95 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 95 | 35 |
| Gemtesa | Vibegron | 91 | 27 |
| Metformin Hcl Er | Metformin Hcl | 86 | 28 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 82 | 21 |
| Metformin Er Gastric | Metformin Hcl | 77 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 23 |
| Prolia | Denosumab | 74 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 69 | 22 |
| Estradiol | Estradiol | 69 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 66 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 66 | 18 |
| Mounjaro | Tirzepatide | 62 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 13 |
| Synthroid | Levothyroxine Sodium | 60 | suppressed |
| Celecoxib | Celecoxib | 59 | 23 |
| Memantine Hcl | Memantine Hcl | 59 | 12 |
| Mirtazapine | Mirtazapine | 58 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 57 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | 12 |
| Fenofibrate | Fenofibrate | 55 | 19 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 54 | 23 |
| Diclofenac Epolamine | Diclofenac Epolamine | 54 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 35 |
| Ammonium Lactate | Ammonium Lactate | 52 | 23 |
| Nifedipine Er | Nifedipine | 52 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 44 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 52 | 15 |
| Hydrocortisone | Hydrocortisone | 51 | 33 |
| Latanoprost | Latanoprost | 50 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 50 | 14 |
| Torsemide | Torsemide | 50 | 13 |
| Valacyclovir | Valacyclovir Hcl | 49 | 25 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 48 | 16 |
| Ezetimibe | Ezetimibe | 47 | 11 |
| Febuxostat | Febuxostat | 47 | 13 |
| Zenpep | Lipase/Protease/Amylase | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 46 | 45 |
| Novolog Flexpen | Insulin Aspart | 46 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Amoxicillin | Amoxicillin | 44 | 40 |
| Methimazole | Methimazole | 44 | 11 |
| Telmisartan | Telmisartan | 44 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Mupirocin | Mupirocin | 41 | 27 |
| Ondansetron Odt | Ondansetron | 41 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 12 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 16 |
| Nystatin | Nystatin | 39 | 21 |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 13 |
| Doxepin Hcl | Doxepin Hcl | 37 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Fluconazole | Fluconazole | 35 | 27 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | 20 |
| Naproxen | Naproxen | 34 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 11 |
| Colchicine | Colchicine | 30 | 19 |
| Metronidazole | Metronidazole | 30 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 21 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Baclofen | Baclofen | 26 | 15 |
| Cephalexin | Cephalexin | 26 | 22 |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 23 |
| Acyclovir | Acyclovir | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Restasis | Cyclosporine | 24 | 12 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | 13 |
| Calcitriol | Calcitriol | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | 11 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 18 |
| Loperamide | Loperamide Hcl | 19 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Xiidra | Lifitegrast | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 11 |
| Risperidone | Risperidone | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Brinzolamide | Brinzolamide | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Isoniazid | Isoniazid | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lasix | Furosemide | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.69 · 14 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Cologuard Collection Kit, FARXIGA, GEMTESA, GVOKE HYPOPEN, Korlym, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error